Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular Lymphoma
September 28th 2023Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.
Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
September 28th 2023Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.
Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML
September 27th 2023Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.
Novel Combinations Seek to Build Off Lenalidomide/Rituximab Backbone in Indolent Lymphoma
Paolo Strati, MD, discusses novel combinations for the treatment of indolent B-cell lymphoma, emphasizes the primary goal of improving the efficacy of immunotherapy and providing patients with chemotherapy-free treatment options, and highlights ongoing trials are investigating various approaches to enhance the activity of lenalidomide/rituximab
Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML
September 22nd 2023Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.
Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.
Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL
Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.
Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
September 18th 2023Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL
September 15th 2023Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.
Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma
September 15th 2023Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.
Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS
September 9th 2023Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.
Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma
September 8th 2023Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.
Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL
The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.